Skip to content

New Method for Real-time Detection of Tissue Ischemia (ISCALERT)

New Method for Real-time Detection of Tissue Ischemia; IscAlert™ - Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04879875
Acronym
ISCALERT
Enrollment
50
Registered
2021-05-10
Start date
2021-09-01
Completion date
2022-07-24
Last updated
2024-04-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biosensing Techniques, Blood Circulation Disorder, Carbon Dioxide, Ischemia

Keywords

Ischemia, Carbon dioxide, Biosensor, Musculature, Subcutaneous, Surgery, Orthopedic, Limb

Brief summary

This is a prospective, single arm, open, single centre clinical investigation designed to examine the feasibility and safety of the IscAlert™ device in patients scheduled for limb (arm/leg) surgery with tourniquet. IscAlert is measuring CO2 in muscular and subcutaneous tissue. IscAlert is inserted into normal muscle and subcutaneous tissue in ischemic (operated limb with a tourniquet) and non-ischemic limb (non-operated limb).After the tourniquet is inflated, ischemia develops in the muscles and subcutaneous tissue. This will result in an increase in CO2, which will be detected by the sensors on the operated extremity, while the sensors on the non-operated will show normal values. After releasing the tourniquet cuff, the muscle will be reperfused and the CO2 level is expected to decrease into normal levels. 50 number of patients will be enrolled to undergo the procedures. The IscAlert will be removed from the patient before the patient is discharged from the operating room, but in 25 of the patients, IscAlert™ will be inserted for 72 hours in the operated extremity after the end of surgery. After this, the sensors are removed. 250 Devices is planned to be used in this clinical study.

Detailed description

This is a prospective, single arm, open, single centre clinical investigation designed to examine the feasibility and safety of the IscAlert™ device in patients scheduled for limb (arm/leg) surgery with tourniquet. 50 number of patients will be enrolled to undergo the procedures detailed in this clinical investigational plan using 250 devices. IscAlert is 0.8 mm in diameter and in vitro testing, shows stable and accurate measurements of pCO2. More than 100 animal experiments have been done with the sensor. The experiments have shown that the sensor detects ischemia (Increased CO2-measurements) in real time in the following organs and tissues: Brain, heart, liver, kidneys, pancreas, intestines, musculature and subcutaneous tissue. Sensitivity and specificity are close to 100%. The sensors are inserted into tissue by a split needle technique. The split needle is the size of a 3-gauge peripheral venous catheter. In animal studies, no complications have been detected when using the sensor. The IscAlert catheters are connected to an electronics unit that is fixed to the skin with an adhesive plaster outside the sterile area. The electrical signals are redirected to a PC approved for clinical use which continuously records tissue pressures of CO2. IscAlert sensors (3 - three) are inserted into normal muscle and subcutaneous tissue proximal on the limb to be operated. The insertion is distal to the blood cuff, and far away from the surgery field. The insertion is done under sterile conditions in accordance with standard sterility criteria at the hospital. No pain during insertion will occur because of insertion is performed after anesthesia induction. Also, the insertion can be compared to an intramuscular injection. Two identical IscAlert sensors are also inserted in the opposite extremity that is not to be operated and serves as a reference value. After the tourniquet is inflated, ischemia develops in the muscles and subcutaneous tissue. This will result in an increase in CO2, which will be detected by the sensors on the operated extremity, while the sensors on the non-operated will show normal values. After releasing the tourniquet cuff, the muscle will be reperfused and the CO2 level is expected to decrease into normal levels within 15 - 45 minutes. In 25 patients, the biosensors will be removed from the patient before the patient is discharged from the operating room, but in 25 of the patients, IscAlert will be inserted for up to 72 hours in the operated extremity after the end of surgery to identify drifting of the sensors. After this, the sensors are removed. The primary objective is to evaluate the ability of the IscAlert device to measure CO2-levels in ischemic and non-ischemic limb musculature and subcutaneous tissue in patients who experience orthopedic surgery with limb tourniquet and to assess the safety/efficacy using device IscAlert. Our hypotheses are: The IscAlert device will be able to detect the presence of ischemia in muscle and subcutaneous tissue, whereby CO2 levels, measured by IscAlert, will be higher in ischemic musculature than non-ischemic musculature in patients undergoing orthopedic limb surgery. No clinically significant bleeding or infection will occur using IscAlert in this clinical study.

Interventions

DEVICEIscAlert

3 IscAlert sensors in the limb undergoing surgery and two control sensors in the opposite limb are inserted and CO2 is measured continously. IscAlert sensors are removed after end of surgery.

DEVICEIscAlert 72h

3 IscAlert sensors in the limb undergoing surgery and two control sensors in the opposite limb are inserted and CO2 is measured continously. IscAlert sensors are removed 72 hours after end of surgery

Sponsors

European Commission
CollaboratorOTHER
Oslo University Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

Prospective, Cohort

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients must be scheduled for orthopedic limb surgery with planned use of tourniquet. * Subject must be ≥ 18 years * Able to give written signed informed consent * Tourniquet planned to be used \> 30 minutes

Exclusion criteria

* Sign of inflammation/infection, hematoma, and traumatized tissue at insertion site

Design outcomes

Primary

MeasureTime frameDescription
Tissue CO2-level72 hoursTissue CO2-level (kPa) during insertion periode

Secondary

MeasureTime frameDescription
Infection30 daysInfection from insertion site at the discretion of the investigator (yes or no)
Pain score at insertion site - Numerical Rating Scale (NRS) - 30 days after discharge from hospital30 daysPain from insertion site measured by Numeric Rating Scale (NRS; 0-10 points)
Pain score at insertion site - Numerical Rating Scale (NRS) - 7 days after discharge from hospital7 daysPain from insertion site measured by Numeric Rating Scale (NRS; 0-10 points)
Arterial CO2 level3 hoursBlood gass analysis of CO2 during surgery (kPa)
Arterial lactate level3 hoursBlood gass analysis of lactate during surgery (mmol/L)
Arterial pH level3 hoursBlood gass analysis of pH during surgery
Bleeding72 hoursAmount of blood from insertion site (ml)
Time of tourniquet180 minutesMinutes of inflated tourniquet during surgery (minutes)
End-tidal level of CO24 hoursEnd-tidal level of CO2 during anesthesia (kPa)
End-tidal level of CO2 72 hours72 hoursEnd-tidal level of CO2 during postoperative recovery (kPa)
Duration of surgery180 minutesDuration of surgery - Number of minutes
Duration of anesthesia240 minutesDuration of anesthesia - Number of minutes
Arterial O2 level3 hoursBlood gass analysis of O2 during surgery (Kpa)

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026